| 摘要 |
<p>Flunisolide, 6.alpha.-fluoro-11.beta.,21-dihydroxy-16.alpha.,17.alpha.-isopropyl i-denedioxypregaa-1,4-diene-3,20-dione, is administered by inhalation in a therapeutically effective dosage to a person having a respiratory disease such as bronchial asthma and allergic rhinitis. A unique crystalline polymorphic form of flunisolide is prepared by contacting one of the other polymorphic forms of solid flunisolide with a suitable liquid in which flunisolide has substantially no solubility, especially Freon? 12 or Freon? 114 or by recrystallizing the unique crystalline form from a suitable solvent such as methylene chloride. The unique crystalline form is stable in aerosols such as Freon? mixtures and is valuable in the treatment of respiratory diseases.</p> |
